Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive February 1, 2006 Jill Wechsler	Washington Report: Cross-Agency Collaboration for Part D Medicare Part D gives CMS more clout over coverage, pricing, and even drug development.
InternetNews March 23, 2009 Kenneth Corbin	Will Wireless IT Rescue Healthcare? Experts and advocates call for a new approach to healthcare that embraces wireless technology to lower costs.
InternetNews February 28, 2008	Google Eyes Medical Records, Data Sharing Business Google has unveiled a plan to help U.S. patients gain control of their medical records and is working with doctors' groups, pharmacies and labs to help them securely share sensitive health data.
Managed Care June 2002	Oncologists: FDA needs to speed up approval of cancer-fighting drugs A Competitive Enterprise Institute survey of cancer specialists found that almost 8 of 10 oncologists think the FDA's approval process has "hurt their ability, at least once in their medical careers, to treat patients with the best possible care."
Pharmaceutical Executive February 1, 2007 Sarah Houlton	Global Report: Under One Roof The UK government is planning to set up a single body to oversee all health research in universities and hospitals - and to facilitate partnerships between government agencies and industry.
The Motley Fool November 22, 2006 Brian Lawler	How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line.
Bio-IT World August 13, 2003 Brian Reid	Remaking the FDA New commissioner is pushing for greater use of technology and innovation to speed the flow of drugs to market.
The Motley Fool January 30, 2009 Brian Orelli	The Health Benefits of Obama's IT Obsession Digital health records are on their way. Which companies are ready to benefit from this new technology?
BusinessWeek April 23, 2009 Catherine Arnst	Doctors' Pride: A Hurdle to Digital Medicine A forerunner in New England found that some physicians would sooner cut ties than see their elite status threatened.
Pharmaceutical Executive August 1, 2008 Jill Wechsler	Can Sentinel Save Drug Development? FDA's new sentinel system shows the pendulum swing toward safety won't swing back anytime soon.
The Motley Fool December 6, 2005 Stephen D. Simpson	Tysabri Tries Again Will the FDA finally approve Elan's multiple sclerosis drug? Investors' fingers are crossed.
CIO December 15, 2009 Kim S. Nash	Data Sharing That Benefits Customers At Children's Hospital Boston, sharing more data, securely, promises healthier, more satisfied patients.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool March 28, 2011 Brian Orelli	Investors Jump for Yervoy! The Food and Drug Administration approval of Bristol-Myers Squibb's Yervoy came with some surprising labeling news.
Insurance & Technology August 25, 2004 Marianne Kolbasuk McGee	EMR Initiative: BCBSMA Steals a March One Massachusetts community is going to find out if electronic medical records really can deliver revolutionary improvements in the quality and cost of healthcare.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool July 31, 2007 Brian Orelli	GPC Takes a Pit Stop The biotech company pulls its New Drug Application for Satraplatin. There is something twisted about having to wait to get a drug to market because it's performing better than expected. Investors, take note.
The Motley Fool May 2, 2011 Tim Beyers	Spectrum Pharmaceuticals Shares Popped: What You Need to Know Shares of Spectrum Pharmaceuticals rose as much as 14% in intraday trading after the Food and Drug Administration approved Fusilev as a colon cancer treatment.
The Motley Fool February 23, 2010 Brian Orelli	The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston.
Pharmaceutical Executive October 1, 2005 Alana Klein	Ad Agencies to the Rescue Faced with strict guidelines and regulatory pressures over advertising, pharmaceutical clients are looking to their agencies for support and guidance.
Pharmaceutical Executive March 1, 2011 Jill Wechsler	New Tools Track Safety, Value in Medicine FDA's Sentinel Initiative raises broader questions about tapping patient information and health IT for comparative studies in drug development.
Chemistry World September 24, 2010 Andrew Turley	End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use.
Chemistry World March 1, 2010 Rebecca Trager	US launches new regulatory science program Two major US government agencies have partnered to create a new regulatory science program to ensure better integration between cutting edge science and regulatory processes in assessing new medical products or compounds flowing from biomedical research.
The Motley Fool November 21, 2008 Brian Orelli	The Comeback of the Century? AstraZeneca is trying to revive Iressa.
Pharmaceutical Executive June 1, 2005 Jill Wechsler	Washington Report: "D" Is for Data It is critical for Medicare to address important questions on drug safety and utilization, and about how prescribing decisions affect health outcomes and costs.
Pharmaceutical Executive December 1, 2006 Richard A. Epstein	FDA vs. the Individual In this excerpt from his important new book Overdose, an ever controversial legal scholar argues that the current system overvalues risk, ignores individual differences, and deprives patients of valuable treatments.
Bio-IT World October 2006 Eric K. Neumann	The Advantages of a Drug Safety Commons Once a Drug Safety Commons has been established, a variety of derivative applications will be developed that can access as well as update the information in organized ways and used by industry researchers internally.
Chemistry World April 24, 2008 James Mitchell Crow	FDA takes tough line on biologic drug The US Food and Drug Administration has rejected an application from biotechnology firm Genzyme to make its already-approved, protein-based drug Myozyme in larger batches.
The Motley Fool November 4, 2008 Brian Orelli	Does the Supreme Court Control Your Investment? The Supreme Court is about to make a decision that could affect drug company investors.
InternetNews October 14, 2010	Defense, Homeland Security Team in Cyber Push Top military and civilian agencies join forces to pool resources and share personnel in the ongoing struggle to preempt and combat threats against U.S. digital systems.
Investment Advisor June 2010 Melanie Waddell	The Regulators Never Sleep The SEC and the CFTC have formed a joint committee that will address emerging regulatory issues.
Pharmaceutical Executive May 1, 2007 Weiner & Hovde	Critical Mass for Critical Path? Everyone agrees that it's the road to pharma's future, but no one's rushing to take it. Yet with growing FDA advocacy and new advances in biomarkers and drug-disease modeling, the rewards of collaboration now look greater than the risks.
Food Processing July 2005 David Joy	Regulatory Issues: What's in a name? The Food and Drug Administration and the U.S. Dept. of Agriculture recently published a joint proposal to amend their regulations dealing with food "standards of identity."
Pharmaceutical Executive July 3, 2007	Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work.
The Motley Fool January 31, 2007 Brian Lawler	FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer.
CIO August 1, 2005 Susannah Patton	An End to Medical Forms? Patients could keep all their medical information online using iHealthRecord, a new service that Medem (a joint venture of the American Medical Association and six other medical societies) introduced in May.
Bio-IT World August 13, 2003 John Rhodes	Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert.
BusinessWeek February 28, 2005 Capell & Carey	A Drug Watchdog To Rival The FDA Europe's agency will soon have new powers. Will it take the lead on safety?
Pharmaceutical Executive February 1, 2006 Bryan Luce	Back Page: Taking Hold of the Wheel Healthcare decision makers do not consistently consider drugs' value. FDA needs to be pressured to change its stance on communicating economic evidence.
Pharmaceutical Executive January 1, 2006 Clinton & Wechsler	What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay?
Pharmaceutical Executive April 1, 2006 Jill Wechsler	Washington Report: A Warning Trend Washington's new answer to drug safety concerns is more warnings and more disclosure of undigested data. But warnings can go too far. Haven't FDA's critics ever heard the story of the boy who cried wolf?
Bio-IT World April 15, 2003 Heller & Philbin	Part 11: The FDA's New View The FDA now has a softer perspective on enforcement, but companies will still have to watch their step.
The Motley Fool February 4, 2009 Brian Orelli	Not If, but When, for Lilly At least Lilly now knows that it's just a matter of time until the anti-clotting agent wins FDA approval.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
The Motley Fool January 31, 2008 Brian Lawler	A Zettlement for Zyprexa? Eli Lilly may be close to resolving a government lawsuit over improper marketing.
Fast Company April 2012 Christina Chaey	Stevi Riel Provides Partnerships With Hospitals To Find Affordable Help For Patients This year, the U.S. government started a program for health-care innovators. One innovator, Stevi Riel takes what physicians are too busy to do, and partners with hospitals to find affordable prescription solutions for underinsured patients.
The Motley Fool October 2, 2007 Brian Orelli	Amylin's Bittersweet FDA News Diabetes drug moves ahead, but not as much as the company wanted. If the FDA rejection was due to safety issues, that wouldn't bode well for Amylin's plans to develop the active ingredient in SYMLIN as a weight-loss drug. Investors, take note.
The Motley Fool February 22, 2008 Brian Orelli	Google in Your Medicine Cabinet Does Google have what the others don't as it moves one step closer to launching its health-care website?
The Motley Fool October 17, 2007 Brian Orelli	FDA Warning Might Be a Buying Opportunity The 3%-4% drops in the stock prices of Amylin and Alkermes, Amylin's partner in the development of a sustained-release version of Byetta, could be a good buying opportunity for investors.
The Motley Fool August 17, 2007 Brian Orelli	FDA's Rigor May Boost Sales The FDA is updating labeling of certain blood-thinning drugs, indicating that patients may want to obtain a genetic test prior to taking the medication. This move may lead to increased testing, and hopefully increased prescriptions.